PACTR202103574924457Other未知
A Randomised Parallel-group Multi-centre Study to Evaluate the Effect of Structured Diabetes Self-management Education Versus Standard of Care on Glycaemic Control, Self-efficacy and Quality of Life in Adults in Two Low Resource Settings in Accra Subsequent to COVID-19
Roberta Lamptey0 个研究点目标入组 206 人开始时间: 2021年3月3日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- Other
- 发起方
- 入组人数
- 206
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 19 Year(s) 至 44 Year(s)（—）
- 性别
- All
入选标准
- •1.Self-identified as Ghanaian
- •2.Ability to speak either English and or Twi
- •3.be aged > 18 years
- •4.be receiving treatment at the study site as an out-patient
- •5. be willing to accept the 6-hour DSME intervention
- •6. be physically able to participate
- •7. be primarily responsible for their own care
- •8.be ambulant at time of recruitment
- •9.be able to participate in activities in a group setting
- •10.have permanent residence in Greater Accra
排除标准
- •1.known to have cognitive defects
- •2.known to have type I diabetes
- •3.known to be pregnant at the time of recruitment or planning to become pregnant during the study or have given birth less than three months prior to recruitment
- •4.known to have sickle cell disease
- •5.Participating in another intervention study at time of recruitment
- •6.known to have chronic medical complications of diabetes (cardiac, renal, neuropathy, hepatic) or systemic illness at the time of recruitment
- •7.recruitment of a member of the patients household for this study
研究者
相似试验
已完成
2 期
A multicenter, randomized, parallel-group study to assess the safety and efficacy of adhesion prevention device, BAX 602, in preventing adhesion of heart and great vessels to surroundings after placement of extracorporeal ventricular assist device (VAD)Patients undergoing open surgery for VAD placement to treat acute circulatory failure, who fulfill all the inclusion and exclusion criteria at the time of enrollment will be enrolled as eligible patients.JPRN-UMIN000038998ational Cerebral and Cardiovascular Center30
进行中（未招募）
1 期
Assess Safety and Efficacy of Vilaprisan in Subjects with Uterine FibroidseiomyomaMedDRA version: 21.1Level: LLTClassification code 10046784Term: Uterine fibroidsSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10016628Term: FibroidsSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10022794Term: Intramural leiomyoma of uterusSystem Organ Class: 100000004864EUCTR2016-002855-48-SKBayer AG766
已完成
3 期
A randomized, parallel-group, multicenter study to assess the efficacy and safety of vilaprisan in subjects with uterine fibroidsleiomyomauterine fibroids10013326NL-OMON48550Bayer18
进行中（未招募）
1 期
Assess Safety and Efficacy of Vilaprisan in Subjects with Uterine FibroidseiomyomaMedDRA version: 20.0Level: LLTClassification code 10046784Term: Uterine fibroidsSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10016628Term: FibroidsSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10022794Term: Intramural leiomyoma of uterusSystem Organ Class: 100000004864EUCTR2016-002855-48-CZBayer AG766
进行中（未招募）
1 期
Assess Safety and Efficacy of Vilaprisan in Subjects with Uterine FibroidseiomyomaMedDRA version: 21.1Level: LLTClassification code 10046784Term: Uterine fibroidsSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10016628Term: FibroidsSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10022794Term: Intramural leiomyoma of uterusSystem Organ Class: 100000004864EUCTR2016-002855-48-DEBayer AG1,200